A New Vision for Ophthalmic Innovation
Eyexora is a global ophthalmology company pioneering a hub-and-spoke model to accelerate innovation in eye care. By centralizing R&D, clinical, regulatory, and commercial expertise into one operational engine, we are advancing multiple therapies and devices in parallel. Our diversified global portfolio balances de-risked, clinic-ready programs with high-impact moonshots – reducing cost and time while increasing probability of success.
Hub & Spoke Flexibility
Eyexora’s hub-and-spoke model centralizes key expertise in a central “hub” to drive a portfolio of “spoke” subsidiaries. This accelerates development of distinct opportunities and reduces risk.
Pan-Ophthalmic Approach
Current focus areas span retina, anterior segment diseases, and cell therapy. With expansion into additional high-value markets in areas of significant unmet patient need, through exclusive in-licensing and academic collaborations.
Proven Mechanisms and Moonshots
By diversifying across multiple assets, Eyexora aims to lower risk while accelerating the path to commercialization via both validated mechanisms and high-impact “moonshots.”
Deep and Broad Ophthalmic Development and Commercialization Experience
The Eyexora team brings together experienced entrepreneurs and seasoned drug developers with 100+ years of collective ophthalmology experience and a track record of raising $1B+ in capital. We’ve been engaged in innovation, company building, and value creation for more than four decades.
Synergistic, complementary skills and experience
Proven track record of building value for patients, providers, and investors
Founded, advised, built, capitalized, and exited over 30 companies and products in the vision care and ophthalmology markets
Partnerships
Partnering to Simplify the Path from Discovery to Market
Innovation abounds and often it stagnates due to scientists and academic centers not understanding the necessary steps to translate research into viable market solutions
News
- September 10, 2025
Eyexora aims to accelerate ophthalmology development by centralising expertise
Claiming the title of the first ophthalmology-focused company with a hub-and-spoke business model, Eyexora debuted on Wednesday with seed funding from ClavystBio to build a global portfolio of devices, as well as anterior and posterior segment therapeutics.
- September 10, 2025
Eyexora Launches the First Hub-and-Spoke Model for Accelerating Ophthalmology Innovation
NEW YORK–(BUSINESS WIRE)– Eyexora announced today its launch as the first company founded to accelerate innovation in ophthalmology using a hub-and-spoke model. The company is building a global portfolio starting with collaborations in Singapore and Europe, with its initial assets in-licensed from the Singapore Eye Research Institute (SERI). Eyexora’s seed financing was led by life […]
